Godavari Drugs Limited (BOM:530317)
115.00
-3.40 (-2.87%)
At close: Jul 27, 2026
Godavari Drugs Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 828 | 648 | 659 | 700 | 570 | 492 | |
Market Cap Growth | 25.17% | -1.65% | -5.91% | 22.72% | 15.81% | 42.95% |
Enterprise Value | 1,447 | 1,364 | 1,217 | 1,012 | 870 | 781 |
Last Close Price | 110.00 | 86.02 | 87.46 | 92.95 | 75.74 | 65.40 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 20.52 | 15.84 | 15.04 | 12.61 | 15.07 | 9.39 |
PS Ratio | 0.78 | 0.61 | 0.58 | 0.45 | 0.36 | 0.31 |
PB Ratio | 1.09 | 0.86 | 1.52 | 1.80 | 1.71 | 1.66 |
P/TBV Ratio | 1.09 | 0.86 | 1.52 | 1.80 | 1.71 | 1.66 |
P/FCF Ratio | - | - | - | 13.43 | 14.70 | 8.23 |
P/OCF Ratio | 112.92 | 88.30 | 5.88 | 3.80 | 4.32 | 4.39 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.36 | 1.28 | 1.07 | 0.64 | 0.55 | 0.48 |
EV/EBITDA Ratio | 13.01 | 12.27 | 9.44 | 7.02 | 7.34 | 6.68 |
EV/EBIT Ratio | 16.65 | 15.70 | 11.66 | 8.45 | 8.77 | 7.81 |
EV/FCF Ratio | - | - | - | 19.42 | 22.41 | 13.05 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.01 | 1.01 | 1.48 | 1.48 | 1.72 | 0.78 |
Debt / EBITDA Ratio | 6.87 | 6.87 | 4.99 | 4.00 | 4.83 | 1.97 |
Debt / FCF Ratio | - | - | - | 11.08 | 14.77 | 3.86 |
Net Debt / Equity Ratio | 0.82 | 0.82 | 1.43 | 1.42 | 1.62 | 0.70 |
Net Debt / EBITDA Ratio | 5.56 | 5.56 | 4.81 | 3.82 | 4.57 | 1.78 |
Net Debt / FCF Ratio | -2.38 | -2.38 | -7.04 | 10.58 | 13.98 | 3.48 |
Asset Turnover | 0.62 | 0.62 | 0.82 | 1.23 | 1.43 | 1.68 |
Inventory Turnover | 2.09 | 2.09 | 3.41 | 6.03 | 8.66 | 10.76 |
Quick Ratio | 0.68 | 0.68 | 0.62 | 0.77 | 0.84 | 1.03 |
Current Ratio | 1.31 | 1.31 | 1.08 | 1.08 | 1.18 | 1.29 |
Return on Equity (ROE) | 6.86% | 6.86% | 10.64% | 15.33% | 12.01% | 19.42% |
Return on Assets (ROA) | 3.16% | 3.16% | 4.70% | 5.84% | 5.56% | 6.49% |
Return on Invested Capital (ROIC) | 5.51% | 5.78% | 8.15% | 10.56% | 11.02% | 14.41% |
Return on Capital Employed (ROCE) | 7.50% | 7.50% | 14.90% | 22.70% | 20.80% | 22.90% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 4.94% | 6.31% | 6.65% | 7.93% | 6.64% | 10.65% |
FCF Yield | -31.37% | -40.12% | -13.36% | 7.45% | 6.80% | 12.15% |
Buyback Yield / Dilution | -1.37% | -1.37% | 0.04% | -0.03% | -0.01% | 0.10% |